Global pharmaceutical market could split into two, US pharma owning US and Chinese pharma taking over the rest. Most-favored nation policy will pull many pharmas out of ex-US regions. Now imagine this in combination with another potential policy that's been discussed, which

Biotech investment firm RA Capital has laid off staff at its internal startup incubator, STAT has learned, highlighting the instability among VCs as the biotech industry struggles to right itself.  statnews.com/2025/05/13/ra-…

Quite the headline trio to start Friday in the biopharma world: Novo Nordisk CEO steps down endpts.com/novo-nordisk-c… 3 months & 0 IPOs endpts.com/its-been-three… Calley Means' fighting words to the pharma industry endpts.com/top-rfk-jr-adv…

We're live blogging the PolyBio Research Foundation’s Spring Symposium, a packed day of virtual presentations discussing studies into #LongCOVID’s underlying biology, updates to clinical trials, and research on other complex chronic diseases. bit.ly/43g8dWu

We’re going on a national listening tour to meet directly with pharmaceutical and biotech CEOs. This is a chance for the FDA to listen and gather feedback from those at the front lines of discovery. We are committed to strengthening a regulatory environment that enables

The rise of China in pharma is neatly illustrated in this chart showing the number of cancer trials over the last decade. Phenomenal growth and not showing any signs of slowing up. From IQVIA iqvia.com/insights/the-i…

HHS spox Andrew Nixon says part of the rationale for axing the contract with Moderna is that mRNA technology is "under-tested." His full statement:

Enjoyed chatting with Wall Street Journal about my thoughts on China biotech - “The half-life of a good idea in biotech has been shortened; if you have a good idea, you better act on it quickly" wsj.com/articles/u-s-v…

A CDC official is resigning from role overseeing updates COVID-19 vaccine recommendations In an email to others in group, she said she started in public health to help most vulnerable "that is not something I am able to continue doing in this role" cbsnews.com/news/cdc-offic…

Excited to present at #BIO2025 in Boston, June 16-19! Our VP of Translational Medicine, Patricio O'Donnell, will join a panel discussion moderated by Rowan Walrath 😷 from C&EN (Chemical & Engineering News) on Precision in Practice. See you there! ​ Learn more about our session here: ​convention.bio.org/program-1/ve-e…

There are a LOT of problems with the FDA Commissioner's National Priority Vouchers. First that they're given out by the commissioner. But also: faster drug approvals are good, but these would be faster than any drug approvals ever. Big promises like this should be approached

BREAKING: Top gene therapy regulator forced out at FDA Nicole Verdun and her deputy placed on leave. statnews.com/2025/06/18/top… via Jason Mast and me.